FRI0463 Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2
FRI0463 Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2